Establishment of personalized medicine through analysis of organoid derived from castration-resistant prostate cancer.
Project/Area Number |
18K09134
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 56030:Urology-related
|
Research Institution | Hiroshima University |
Principal Investigator |
TEISHIMA JUN 広島大学, 医系科学研究科(医), 准教授 (20397962)
|
Co-Investigator(Kenkyū-buntansha) |
松原 昭郎 広島大学, 医系科学研究科(医), 専門研究員 (10239064)
坂本 直也 国立研究開発法人国立がん研究センター, 国立がん研究センター・先端医療開発センター, ユニット長 (20571798)
安井 弥 広島大学, 医系科学研究科(医), 教授 (40191118)
林 哲太郎 広島大学, 医系科学研究科(医), 講師 (60612835)
神明 俊輔 広島大学, 病院(医), 助教 (70749936)
井上 省吾 広島大学, 病院(医), 講師 (90457177)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 前立腺癌 / 去勢抵抗性前立腺癌 / オルガノイド / 薬剤感受性 / 泌尿器癌 / 薬剤耐性 |
Outline of Final Research Achievements |
Organoids were established from tissues of the normal prostate, localized prostate cancer, and CRPC. Using these organoids and prostate cancer cell lines, mechanisms through T-UCR and various molecules including KIFC1, MAPT, TUBB3, BUB1B, and procadherin B9. Evidences from these analyses were investigated and comfirmed in other urological malignant diseases.
|
Academic Significance and Societal Importance of the Research Achievements |
オルガノイドはその由来となるヒト検体の組織学的な特徴を忠実に反映しうるモデルであり、症例の薬剤感受性評価に適している。本研究によって、多くの分子を介したCRPCに対する薬剤耐性機構について解明された。オルガノイドによる薬剤感受性のスクリーニングのデータは実臨床での薬剤の効果予測因子として有用なだけでなく、症例ごとに最適な薬剤選択を行う個別化治療を可能にする上で重要な情報となりうる。
|
Report
(4 results)
Research Products
(26 results)
-
[Journal Article] TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer.2021
Author(s)
Sekino Y, Han X, Babasaki T, Miyamoto S, Kobatake K, Kitano H, Ikeda K, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A.
-
Journal Title
Urol Oncol
Volume: 24
Issue: 6
Pages: 112-115
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.2021
Author(s)
Sekino Y, Han X, Kobayashi G, Babasaki T, Miyamoto S, Kobatake K, Kitano H, Ikeda K, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A
-
Journal Title
Oncology
Volume: -
Issue: 4
Pages: 240-250
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma.2020
Author(s)
Han X, Sekino Y, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A.
-
Journal Title
Urol Oncol.
Volume: -
Issue: 6
Pages: 9-17
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3.2020
Author(s)
Teishima J, Hayashi T, Kitano H, Sadahide K, Sekino Y, Goto K, Inoue S, Honda Y, Sentani K, Awai K, Yasui W, Matsubara A.
-
Journal Title
Jpn J Clin Oncol.
Volume: 50(4)
Issue: 4
Pages: 473-478
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.2020
Author(s)
Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, Oue N, Teishima J, Matsubara A, Sasaki N, Yasui W.
-
Journal Title
Cancer Sci.
Volume: 111(3)
Issue: 3
Pages: 1020-1027
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.2020
Author(s)
Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, Shigeta M, Kobayashi K, Kajiwara M, Kadonishi Y, Tacho T, Matsubara A.
-
Journal Title
Int Urol Nephrol.
Volume: 52(1)
Issue: 1
Pages: 77-85
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.2019
Author(s)
Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Yasui W, Matsubara A.
-
Journal Title
Int J Mol Sci.
Volume: 20(16)
Issue: 16
Pages: 3936-3936
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
[Journal Article] Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.2019
Author(s)
Sekino Y, Sakamoto N, Ishikawa A, Honma R, Shigematsu Y, Hayashi T, Sentani K, Oue N, Teishima J, Matsubara A, Yasui W.
-
Journal Title
Oncol Rep.
Volume: 41
Pages: 3111-3118
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.2019
Author(s)
Sekino Y, Oue N, Mukai S, Shigematsu Y, Goto K, Sakamoto N, Sentani K, Hayashi T, Teishima J, Matsubara A, Yasui W.
-
Journal Title
Prostate
Volume: 79
Issue: 2
Pages: 234-242
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
[Presentation] KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer.2018
Author(s)
Sekino Y, Koike Y, Shigematsu Y, Hattori T, Sakamoto N, Shiota M, Sentani K, Oue N, Teishima J, Matsubara A, Yasui W
Organizer
第77回日本癌学会総会
Related Report
-